Next-Generation Bispecific Nanobody Targeting CD274 and CD40 for Advanced Colon Cancer Immunotherapy

VHH-P430 is a fully humanized bispecific nanobody engineered to simultaneously target the CD274 molecule (CD274) and the CD40 molecule (CD40), both of which play pivotal roles in tumor immunomodulation. Developed using an innovative in vitro assembly strategy, VHH-P430 integrates specialized single-domain antibody fragments in a robust molecular framework, which is currently undergoing biological testing. This bispecific antibody holds significant therapeutic potential for the management of colon cancer by leveraging dual immune pathways, offering a differentiated approach among emerging biotherapeutics.

Licensing Opportunity

VHH-P430 is actively open for out-licensing and collaborative partnership opportunities. Leading biopharmaceutical companies and research organizations are invited to explore this promising bispecific nanobody program for colon cancer immunotherapy.

Development Phase

Modality

VHH-P430 utilizes a unique bispecific format, comprising two half antibodies assembled in vitro. Its design employs single-domain nanobody fragments with the first half antibody containing variable heavy and light chains directed at CD40, fused with a nanobody against CD274. The second half antibody mirrors this structure through a combination of anti-CD40 and anti-CD274 domains, all expressed in HEK-293F cells using knob-into-hole technology. The nanobody’s single-domain structure confers a reduced molecular size, enhanced tissue penetration, and improved stability—an advantage in the treatment of solid tumors such as colon cancer, where deep tumor infiltration and modulation of the tumor microenvironment are crucial.

Target

CD274 is an immune checkpoint molecule broadly expressed on tumor cells, immune cells, and certain normal tissues, where it can suppress cytotoxic T cell activity. CD40, a member of the tumor necrosis factor receptor superfamily, is found primarily on antigen-presenting cells and is implicated in T cell activation and immune priming. Both CD274 and CD40 are increasingly recognized as critical therapeutic targets for colon cancer due to their roles in mediating immune escape and antitumor immunity. By simultaneously targeting CD274 and CD40, VHH-P430 offers a novel strategy to overcome immune suppression while enhancing antigen presentation within the tumor microenvironment. The selection of both CD274 and CD40 as targets positions this program at the forefront of innovative colon cancer immunotherapy, reinforcing significant strategic value for future clinical development.

Mechanism of Action

VHH-P430 exerts its antitumor effect by dual engagement of CD274 and CD40. The nanobody disrupts immune checkpoint signaling through CD274 blockade, alleviating T cell inhibition and promoting immune-mediated tumor cell killing. Concurrently, targeting CD40 facilitates the activation of antigen-presenting cells, enhancing the initiation of adaptive immune responses. As an immune checkpoint inhibitor and signal transduction modulator, VHH-P430 can potentiate both innate and adaptive immunity within the tumor microenvironment. The sophisticated nanobody platform employed allows for further expansion, including antibody-drug conjugates and diversified multispecific formats, broadening the scope for future therapeutic applications.

Colon Cancer

Colon cancer is one of the most commonly diagnosed malignancies worldwide, representing a major global health burden. The disease is characterized by malignant transformation of epithelial cells in the colon, often progressing silently before clinical detection. Established treatment regimens include surgical resection, chemotherapy, radiation therapy, and targeted biologics, with immunotherapy emerging as a new frontier. Despite advances, survival rates for advanced or metastatic colon cancer remain suboptimal, underscoring significant unmet clinical needs. Treatment is often complicated by resistance, tumor heterogeneity, and immunosuppressive microenvironments. By precisely targeting immune checkpoints CD274 and immunostimulatory receptor CD40, VHH-P430 has the potential to address several key resistance pathways, enhance immune response, and improve clinical outcomes in colon cancer. Its bispecific nanobody format is particularly suited to overcoming the barriers of poor immunogenicity and tumor infiltration, offering hope for durable responses.